MicroRNA-362-5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 809-818

  Ni, Fang ^a   Zhao, Hua ^a   Cui, Huaqin ^a   Wu, Zhengsheng ^a   Chen, Li ^a   Hu, Zhongqian ^a   Guo, Chuang ^b   Liu, Yakun ^a   Chen, Zhuo ^a   Wang, Xinyi ^a   Chen, Danlei ^a   Wei, Haiming ^b   Wang, Siying ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

CYLD; Hepatocellular carcinoma; Metastasis; MiR 362 5p

Indexed keywords

CYLINDROMATOSIS PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 362 5P; TUMOR PROTEIN; UNCLASSIFIED DRUG; CYLD PROTEIN, HUMAN; MESSENGER RNA; MIRN362 MICRORNA, HUMAN; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; CYLD GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; METASTASIS; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GENE; TUMOR GROWTH; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL ADHESION; CELL MOTION; DRUG SCREENING; ENZYME IMMUNOASSAY; GENETICS; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MICE; MICE, NUDE; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919487219     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.10.041     Document Type: Article

References (40)

1. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
2. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol 2006, 45:529-538.
3. Giordano S., Columbano A. MicroRNAs: new tools for diagnosis, prognosis and therapy in HCC?. Hepatology 2013, 57:840-847.
4. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142:1264-1273.e1.
5. Sanyal A.J., Yoon S.K., Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010, 15(Suppl. 4):14-22.
6. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
7. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet 2009, 10:704-714.
8. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
9. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
10. Lujambio A., Lowe S.W. The microcosmos of cancer. Nature 2012, 482(2012):347-355.
11. Bentwich I., Avniel A., Karov Y., Aharonov R., Gilad S., Barad O., et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat. Genet 2005, 37:766-770.
12. Deng L.L., Shao Y.X., Lv H.F., Deng H.B., Lv F.Z. Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer cells. Neoplasma 2012, 59:18-29.
13. Massoumi R. CYLD: a deubiquitination enzyme with multiple roles in cancer. Future Oncol 2011, 7:285-297.
14. Hayashi M., Jono H., Shinriki S., Nakamura T., Guo J., Sueta A., et al. Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res. Treat 2014, 143:447-457.
15. Massoumi R., Chmielarska K., Hennecke K., Pfeifer A., Fässler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006, 125:665-677.
16. Massoumi R., Kuphal S., Hellerbrand C., Haas B., Wild P., Spruss T., et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J. Exp. Med 2009, 206:221-232.
17. Zhang J., Stirling B., Temmerman S.T., Ma C.A., Fuss I.J., Derry J.M., et al. Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J. Clin. Invest 2006, 116(11):3042-3049.
18. Wang W.Y., Lim J.H., Li J.D. Synergistic and feedback signaling mechanisms in the regulation of inflammation in respiratory infections. Cell. Mol. Immunol 2012, 9:131-135.
19. Lim J.H., Jono H., Komatsu K., Woo C.H., Lee J., Miyata M., et al. CYLD negatively regulates transforming growth factor-beta-signalling via deubiquitinating Akt. Nat. Commun 2012, 3:771.
20. Tauriello D.V., Haegebarth A., Kuper I., Edelmann M.J., Henraat M., Canninga-van Dijk M.R., et al. Loss of the tumor suppressor CYLD enhances Wnt/betacatenin signaling through K63-linked ubiquitination of Dvl. Mol. Cell 2010, 37:607-619.
21. Pannem R.R., Dorn C., Ahlqvist K., Bosserhoff A.K., Hellerbrand C., Massoumi R. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis 2014, 35:461-468.
22. Gautheron J., Luedde T. A novel player in inflammation and cancer: the deubiquitinase CYLD controls HCC development. J. Hepatol 2012, 57:937-939.
23. Font-Burgada J., Seki E., Karin M. CYLD and HCC: when being too sensitive to your dirty neighbors results in self-destruction. Cancer Cell 2012, 21:711-712.
24. Urbanik T., Köhler B.C., Boger R.J., Wörns M.A., Heeger S., Otto G., et al. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int. J. Oncol 2011, 38:121-131.
25. Chu L., Gu J., He Z., Xiao T., Liu X. Adenoviral vector expressing CYLD augments antitumor activity of TRAIL by suppression of NF-kappaB survival signaling in hepatocellular carcinoma. Cancer Biol. Ther 2006, 5:615-622.
26. Hashimoto K., Mori N., Tamesa T., Okada T., Kawauchi S., Oga A., et al. Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod. Pathol 2004, 17:617-622.
27. Ni F., Sun R., Fu B., Wang F., Guo C., Tian Z., et al. IGF-1 promotes the development and cytotoxic activity of human NK cells. Nat. Commun 2013, 4:1479.
28. Silahtaroglu A.N., Nolting D., Dyrskjot L., Berezikov E., Moller M., Tommerup N., et al. Detection of microRNAs in frozen tissue sections by fluorescence in situ hybridization using locked nucleic acid probes and tyramide signal amplification. Nat. Protoc 2007, 2:2520-2528.
29. Zhang L., Yang L., Liu X., Chen W., Chang L., Chen L., et al. MicroRNA-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through nuclear factor kappa B pathways. Hepatology 2013, 57:1919-1930.
30. Sun S.C. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 2010, 17:25-34.
31. Lee Y.S., Dutta A. MicroRNAs: small but potent oncogenes or tumor suppressors. Curr. Opin. Investig. Drugs 2006, 7:560-564.
32. Otsuka M., Kishikawa T., Yoshikawa T., Ohno M., Takata A., Shibata C., et al. The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects. J. Gastroenterol 2014, 49:173-184.
33. Trompouki E., Hatzivassiliou E., Tsichritzis T., Farmer H., Ashworth A., Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003, 424:793-796.
34. Brummelkamp T.R., Nijman S.M., Dirac A.M., Bernards R. Loss of the cylindromatosis tumor suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003, 424:797-801.
35. Ye H., Liu X., Lv M., Wu Y., Kuang S., Gong J., et al. MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids Res 2012, 40:5201-5214.
36. Iliopoulos D., Jaeger S.A., Hirsch H.A., Bulyk M.L., Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 2010, 39:493-506.
37. Soifer H.S., Rossi J.J., Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol. Ther 2007, 15:2070-2079.
38. Park J.K., Kogure T., Nuovo G.J., Jiang J., He L., Kim J.H., et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res 2011, 71:7608-7616.
39. Callegari E., Elamin B.K., Giannone F., Milazzo M., Altavilla G., Fornari F., et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 2012, 56:1025-1033.
40. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.